Dr Reddys unveils generic version of Zyban ER tablets in US
The company has launched Bupropion hydrochloride extended-release tablets USP (SR), approved by the United States Food and Drug Administration (USFDA), Dr Reddys said in a filing to BSE.
New Delhi: Dr Reddy's Laboratories on Thursday said it has launched in the US generic Bupropion hydrochloride extended-release tablets indicated as an aid to smoking cessation treatment.
The company has launched Bupropion hydrochloride extended-release tablets USP (SR), approved by the United States Food and Drug Administration (USFDA), the drug firm said in a filing to BSE.
Read Also: Dr Reddys gets 8 USFDA observations for Duvvada facility in Andhra Pradesh
The product is a generic version of GSK group of companies' Zyban extended-release tablets, it added.
According to IQVIA Health, the Zyban brand and generic had US sales of around USD 5.4 million MAT for the 12 months ended June 2019, the company said.
Dr Reddy's tablets are available as 150 mg dosage strength in bottle count sizes of 60, it added.
Read Also: Dr Reddy's launches generic version of Sabril powder in US to treat epilepsy
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd